Avanos Medical (NYSE:AVNS) Sees Strong Trading Volume – What’s Next?

Posted by George Bondi on May 24th, 2026

Avanos Medical, Inc. (NYSE:AVNS – Get Free Report) saw an uptick in trading volume on Friday . 2,564,317 shares were traded during mid-day trading, an increase of 141% from the previous session’s volume of 1,064,897 shares.The stock last traded at $24.6550 and had previously closed at $24.70.

Analyst Ratings Changes

Several brokerages have commented on AVNS. Zacks Research lowered shares of Avanos Medical from a “hold” rating to a “strong sell” rating in a report on Thursday, May 7th. Weiss Ratings upgraded shares of Avanos Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 22nd. Finally, Wall Street Zen lowered shares of Avanos Medical from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Two research analysts have rated the stock with a Sell rating, According to data from MarketBeat, Avanos Medical currently has an average rating of “Sell”.

View Our Latest Report on AVNS

Avanos Medical Stock Down 0.2%

The company has a market cap of $1.15 billion, a P/E ratio of -15.31 and a beta of 1.58. The company’s 50-day moving average is $19.67 and its two-hundred day moving average is $15.01. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.48 and a quick ratio of 1.40.

Avanos Medical (NYSE:AVNS – Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.16 by $0.06. The business had revenue of $182.20 million during the quarter, compared to analyst estimates of $170.00 million. Avanos Medical had a positive return on equity of 5.39% and a negative net margin of 10.39%.The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.26 EPS. As a group, equities analysts predict that Avanos Medical, Inc. will post 1.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Avanos Medical

Several large investors have recently bought and sold shares of AVNS. Northwestern Mutual Wealth Management Co. increased its holdings in Avanos Medical by 1,596,514.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 14,896,413 shares of the company’s stock worth $167,287,000 after buying an additional 14,895,480 shares in the last quarter. Armistice Capital LLC increased its holdings in Avanos Medical by 28.0% in the 4th quarter. Armistice Capital LLC now owns 3,200,000 shares of the company’s stock worth $35,936,000 after buying an additional 700,000 shares in the last quarter. Millennium Management LLC increased its holdings in Avanos Medical by 312.4% in the 3rd quarter. Millennium Management LLC now owns 896,242 shares of the company’s stock worth $10,361,000 after buying an additional 678,898 shares in the last quarter. Ameriprise Financial Inc. increased its holdings in Avanos Medical by 356.6% in the 3rd quarter. Ameriprise Financial Inc. now owns 591,181 shares of the company’s stock worth $6,834,000 after buying an additional 461,706 shares in the last quarter. Finally, Citadel Advisors LLC increased its holdings in Avanos Medical by 212.0% in the 3rd quarter. Citadel Advisors LLC now owns 574,104 shares of the company’s stock worth $6,637,000 after buying an additional 390,082 shares in the last quarter. 95.17% of the stock is currently owned by institutional investors.

Avanos Medical Company Profile

(Get Free Report)

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.